Cumberland Pharmaceuticals (CPIX) EBITDA (2010 - 2026)

Cumberland Pharmaceuticals has disclosed EBITDA across 17 years of filings, most recently posting -$3.2 million for Q2 2026.

• In Q2 2026, EBITDA fell 1.31% year-over-year to -$3.2 million; the TTM figure through Jun 2026 stood at -$9.6 million (down 79.46% YoY), while the FY2025 annual figure was -$2.8 million, up 56.59% from the prior year.
• EBITDA came in at -$3.2 million for Q2 2026 at Cumberland Pharmaceuticals, down from -$3.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.3 million in Q1 2025 to a low of -$6.2 million in Q4 2023.
• Average EBITDA over 5 years is -$1.8 million, with a median of -$1.8 million recorded in 2022.
• Year-over-year, EBITDA tumbled 4591.4% in 2024 and surged 169.12% in 2025.
• Over 5 years, EBITDA stood at -$2.3 million in 2022, then sank by 171.28% to -$6.2 million in 2023, then surged by 70.19% to -$1.8 million in 2024, then gained by 25.56% to -$1.4 million in 2025, then slumped by 130.49% to -$3.2 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$3.2 million in Q2 2026, -$3.1 million in Q1 2026, and -$1.4 million in Q4 2025.